<DOC>
	<DOCNO>NCT00780663</DOCNO>
	<brief_summary>This Phase 2 , open-label , multicenter , efficacy safety study quarfloxin patient low intermediate grade neuroendocrine cancer . The purpose study evaluate rate clinical benefit response quarfloxin treatment include reduction secretory symptom flush and/or diarrhea reduction quantifiable hormone biochemical tumor marker .</brief_summary>
	<brief_title>Quarfloxin Patients With Low Intermediate Grade Neuroendocrine Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>Histologically cytologically confirm low intermediate grade neuroendocrine carcinoma include carcinoid islet cell cancer . Patients neuroendocrine tumor associate MEN1 syndrome eligible . Measureable disease RECIST Unresectable metastatic disease Secretory symptom diarrhea flush attribute carcinoid tumor and/or quantifiable hormone biochemical marker Males females 18 year age old . Zero two prior cytotoxic chemotherapy regimen . Patients may receive concomitant octreotide Sandostatin® Patients must central IV access , agree insertion central IV line . All previous cancer therapy , radiation , surgery , must discontinue least 21 day prior start treatment . Acceptable liver function Acceptable renal function Acceptable hematologic status ECOG Performance Status ≤1 . Anticipated survival least 6 month . Able maintain patient diary . For men woman childproducing potential , use effective contraceptive method study one month discontinuation treatment . Ability understand requirement study , provide write informed consent agree abide study restriction return clinic require assessment . Poorly differentiated neuroendocrine carcinoma , highgrade neuroendocrine carcinoma , adenocarcinoid , goblet cell carcinoid small cell carcinoma . Pregnant nursing woman . Severe chronic obstructive pulmonary disease hypoxemia uncorrectable pulmonary compromise . Seizures control anticonvulsant therapy . Participation investigational drug study within 28 day quarfloxin administration currently receive investigational therapy . Patients second malignancy require active treatment . Active symptomatic bacterial , fungal , viral infection include active HIV viral hepatitis . Prior treatment quarfloxin . Clinically significant bleeding event within last 3 month , unrelated trauma , underlying condition would expect result bleed diathesis . Patients exhibit allergic reaction similar structural compound formulation . Any illness condition opinion investigator may affect safety treatment evaluation study 's endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Neuroendocrine</keyword>
	<keyword>Carcinoid</keyword>
	<keyword>NET</keyword>
	<keyword>MEN-1</keyword>
	<keyword>Islet cell</keyword>
</DOC>